BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 9, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 1, 2006
View Archived Issues
Q1 developments at Ono
Read More
sanofi-aventis: H1 review
Read More
New KCa channel activator a promising strategy for micturition control
Read More
Novel treatment options for metabolic disorders described in recent patents
Read More
sanofi-aventis patents novel cannabinoid CB1 receptor antagonists
Read More
New strategies for treatment of glaucoma reported in recent patents
Read More
New anxiolytics disclosed in a recent Ono patent
Read More
Alzheimer's disease candidate AL-108 begins phase Ib study
Read More
Phase II study of GV-1001 in hepatocellular carcinoma cleared to begin in France
Read More
Obesity drug candidate BVT-74316 enters phase I testing
Read More
Positive phase I results for universal allergy immunotherapy RP-01
Read More
Enrollment completed in iloperidone and VEC-162 phase III trials
Read More
MLN-0415 studied in phase I for inflammatory disorders
Read More
SBIR grant to support Velcura's research into processes in bone formation
Read More
Novel delta opioid agonist ADL-5859 begins phase I study
Read More
ChemDiv and Yale receive NIH grant for adrenal gland disorder research
Read More
Roche discontinues codevelopment of daclizumab in asthma
Read More
New preclinical data for shingles compound FV-100
Read More
Genzyme to initiate tender offer for AnorMED
Read More
MolecularMD to support phase II study of Ablvax
Read More
MediGene to acquire Avidex
Read More
PR-104, a hypoxia-activated prodrug under clinical development for cancer
Read More
Bristol-Myers Squibb report on new potent and selective FXa inhibitor
Read More
GSK reports on SB-737050A, their new targeted lead candidate for schizophrenia
Read More
